← Back to Search

Radiation Therapy

SABR for Cancer

N/A
Waitlist Available
Led By Robert Olson, MD
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance status 0-2
All brain metastases cases need approval from Stereotactic Radiosurgery (SRS) rounds
Must not have
Clinical or radiological evidence of spinal cord compression
Complete response to first-line chemotherapy (i.e. no measurable target for SABR)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at approximately the end of year 5
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new cancer treatment and measuring its toxicity. There is potential for the treatment to improve survival for people with a certain type of cancer.

Who is the study for?
This trial is for people with a limited number of cancer spread sites (up to 5), who've had their primary tumor treated, and are not candidates for surgery. They should be in relatively good health otherwise, able to consent, and complete questionnaires in English. Pregnant women or those with certain medical conditions that make radiotherapy unsafe cannot join.
What is being tested?
The study tests Stereotactic Ablative Body Radiotherapy (SABR) on patients with few metastatic cancer sites. It aims to assess the side effects and potential survival benefits of this targeted high-dose radiation therapy compared to other treatments.
What are the potential side effects?
Potential side effects include skin reactions at the treatment site, fatigue, nausea, pain or swelling around the treated area. There may also be risks specific to where the SABR is directed; for example, lung inflammation if treating chest metastases.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and am up and about more than half of the day.
Select...
My brain metastases have been approved for treatment by a specialized team.
Select...
I am not a candidate for surgery to remove my cancer as advised by my medical team.
Select...
My cancer has spread, and this was confirmed by tests.
Select...
My primary cancer was treated with intent to cure or controlled with prior therapy.
Select...
My non-brain cancer spot is no larger than 3cm if treated with a single radiation dose.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have signs of pressure on my spinal cord.
Select...
My first chemotherapy fully eliminated the cancer that can be measured.
Select...
My cancer cannot be treated with the goal of removing it completely.
Select...
I have health conditions that prevent me from receiving radiation therapy.
Select...
My cancer has spread to my thigh bone and there's a high risk it might break.
Select...
I need surgery to relieve pressure in my brain from cancer.
Select...
I have ongoing fluid buildup due to cancer in the lining of my lung.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at approximately the end of year 5
This trial's timeline: 3 weeks for screening, Varies for treatment, and at approximately the end of year 5 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Patient-reported Quality of life, function and health status using BC Cancer's Prospective Outcomes and Support Initiative (POSI).
Toxicity as Assessed by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4 for each organ treated (e.g. liver, lung, bone)]
Secondary study objectives
Lesional control rate, defined as lack of further progression
Overall survival
Progression-free survival

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stereotactic armExperimental Treatment1 Intervention
Stereotactic ablative radiotherapy

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
175 Previous Clinical Trials
93,829 Total Patients Enrolled
Robert Olson, MDPrincipal InvestigatorBC Cancer Agency - Centre for the North
1 Previous Clinical Trials
204 Total Patients Enrolled

Media Library

Stereotactic Ablative Body Radiotherapy (SABR) (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02933242 — N/A
Cancer Research Study Groups: Stereotactic arm
Cancer Clinical Trial 2023: Stereotactic Ablative Body Radiotherapy (SABR) Highlights & Side Effects. Trial Name: NCT02933242 — N/A
Stereotactic Ablative Body Radiotherapy (SABR) (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02933242 — N/A
~27 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top